Embedded Files
DelveInsight's "Wet-AMD Pipeline Analysis 2025" delivers extensive intelligence on over 60 pharmaceutical firms and more than 75 investigational medications within the Wet-AMD development arena. The analysis encompasses profiles of Wet-AMD Pipeline therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Wet-AMD Pipeline Therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.
Interested in recent developments within the Wet-AMD Pipeline? Discover the emerging treatments and clinical studies generating attention @ Wet-AMD Pipeline Outlook Report
Primary Highlights from the Wet-AMD Pipeline Analysis
Primary Highlights from the Wet-AMD Pipeline Analysis
On October 30, 2025, NexThera Co. Ltd revealed a Phase 1/2 Investigation to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD).
On October 27, 2025, Kodiak Sciences Inc initiated a Phase 3 Investigation to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration.
DelveInsight's Wet-AMD Pipeline analysis reveals a dynamic field featuring more than 60 engaged entities advancing over 75 investigational treatments for Wet-AMD management.
Major Wet-AMD pharmaceutical firms include Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate, among additional organizations.
Notable Wet-AMD investigational medications include NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316, among others.
Curious about which pharmaceutical companies are pioneering advancement in Wet-AMD treatment? Explore comprehensive pipeline intelligence @ Wet-AMD Clinical Trials Assessment
The Wet-AMD Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Wet-AMD.
Wet-AMD Background
Wet-AMD Background
Wet Age-related Macular Degeneration (AMD) is a chronic eye disease that impacts the macula, the central portion of the retina responsible for sharp, detailed vision. It is a more severe manifestation of AMD compared to the dry type and progresses rapidly, resulting in significant vision loss if untreated. Wet AMD occurs when abnormal blood vessels develop under the macula, leaking blood or fluid, which disrupts retinal function and causes scarring. This condition primarily affects older adults, typically over the age of 50, and represents a leading cause of central vision loss in this age group.
Wet-AMD Investigational Drug Profiles
Wet-AMD Investigational Drug Profiles
RGX-314: REGENXBIO
RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is engineered to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is under development as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions managed with anti-VEGF. REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. Presently, the medication is undergoing Phase III developmental assessment for managing Wet Age-Related Macular Degeneration (AMD).
CLS-AX: Clearside Biomedical
CLS AX is a proprietary axitinib injectable suspension delivered via Clearside's suprachoroidal space (SCS) Microinjector®, engineered as a long-acting treatment for wet age-related macular degeneration (wet AMD). It's a potent, pan VEGF tyrosine kinase inhibitor (TKI) that offers targeted, durable delivery behind the retina, potentially reducing injection frequency while maintaining stable visual acuity. CLS AX has demonstrated positive safety and efficacy in Phase IIb (ODYSSEY) results and is presently being advanced toward a Phase III development program.
SYL1801: Sylentis
SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, through mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections. Presently the medication is undergoing Phase II developmental assessment for managing Wet Age-Related Macular Degeneration (Wet-AMD).
IBI 333: Innovent Biologics
IBI 333 is an investigational bispecific fusion protein created by Innovent Biologics targeting both VEGF A and VEGF C. It's presently in Phase I trials (for neovascular age related macular degeneration), where it is delivered via intravitreal injection to block dual angiogenic pathways and potentially overcome resistance seen with VEGF A monotherapy. Presently the medication is undergoing Phase I developmental assessment for managing Wet Age-Related Macular Degeneration (Wet-AMD).
Monitoring active Wet-AMD Clinical investigations? This announcement is essential reading. Access the latest advances @ Wet-AMD Treatment Drugs
The Wet-AMD Pipeline Analysis Offers Intelligence On:
The Wet-AMD Pipeline Analysis Offers Intelligence On:
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Wet-AMD management, including cumulative therapies created by each organization for this indication.
It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Wet-AMD Treatment.
Wet-AMD pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.
Wet-AMD investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Wet-AMD market.
Wet-AMD Pharmaceutical Firms
Wet-AMD Pharmaceutical Firms
Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate, among additional organizations.
The Wet-AMD Pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:
Intravenous
Subcutaneous
Oral
Intramuscular
Wet-AMD products are classified under various molecular categories including:
Monoclonal antibody
Small molecule
Peptide
From investigational drug candidates to competitive intelligence, the Wet-AMD Pipeline Analysis encompasses comprehensive insights - review it today @ Wet-AMD Market Drivers and Barriers, and Future Perspectives
Scope of the Wet-AMD Pipeline Analysis
Scope of the Wet-AMD Pipeline Analysis
Coverage: Global
Wet-AMD Pharmaceutical Firms: Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate, among additional organizations.
Wet-AMD Investigational Treatments: NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316, among others.
Wet-AMD Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination
Wet-AMD Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III
Stay informed in Healthcare Research - uncover future directions for the Wet-AMD Treatment landscape through this comprehensive analysis @ Wet-AMD Emerging Drugs and Major Players
Table of Contents
Table of Contents
1. Introduction
2. Executive Summary
3. Wet Age-Related Macular Degeneration (Wet-AMD): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-Related Macular Degeneration (Wet-AMD)- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RGX-314: REGENXBIO
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. SYL1801: Sylentis
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. IBI 333: Innovent Biologics
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
21. Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
22. Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
23. Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
24. Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
25. Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
26. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
27. Appendix
About Us
About Us
DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.
Contact Information:
Kanishk
Page updated
Google Sites
Report abuse